Washington ordered a vaccine that doesn’t exist. Here’s what it would actually take to build it.
Trump’s MMR executive order is being covered as a political story. The more consequential question is a manufacturing one — and the answer from the only company that matters is: ten years, maybe more.
On August 10, 2026, President Trump signed an executive order titled “Gold Standard Childhood Vaccine Recommendations” that did two things simultaneously: it cut the CDC’s recommended childhood immunization list from 18 diseases to 11, and it directed that the combined measles-mumps-rubella vaccine be split into three separate single-disease shots administered at separate visits.
The CDC counted more than 2,300 confirmed measles cases by late July — already surpassing the full-year 2025 total — with the count reaching 2,777 by August 20, according to CDC’s own tracker. The country is recording its worst measles year since 1991. cdc
The political reaction was immediate and predictable. Pediatric societies objected. Scientists pushed back. The autism rhetoric that has followed vaccine policy debates for decades resurfaced at the signing. (related opinion story)
US District Judge Brian E. Murphy issued a preliminary injunction on March 16, temporarily blocking the January 2026 immunization schedule overhaul and suspending the authority of Kennedy’s reconstituted ACIP pending a full merits review. The injunction is not a final ruling, the underlying case continues, but the effect is that the pre-January 2026 vaccine schedule stays in force.
What has received considerably less attention is the three separate shots it calls for don’t exist. No monovalent measles, mumps, or rubella vaccines are currently licensed for use in the United States. It’s not ignored in the order itself, as it says the MMR split should happen “once such products are domestically available.”
That phrase does a lot of quiet work. It defers the entire policy to an undefined future date. And it raises the question: what would it actually take to close that gap?
The incumbent’s answer: a decade
There are two companies that manufacture MMR vaccines for the US market. Merck, which makes M-M-R II, and GSK, which makes Priorix, licensed in the US in 2022. Merck is the relevant party for this question, as the longer-standing manufacturer with the deeper dataset on the individual antigens.
Merck has been straightforward about the timeline. “Even under current expedited review pathways, it could take years — potentially as many as 10 — to meet the safety and efficacy requirements to obtain FDA approval and then begin manufacturing and commercialization of single-disease shots”, the company said in a statement. That statement was made in 2025 when Trump first floated the idea, and Merck has not revised it upward since the executive order formalised the request.
To date, there has been no published scientific evidence that shows any benefit in separating the combination MMR vaccine into three individual shots. Use of the individual components of combination vaccines increases the number of injections for the individual and may result in delayed or missed immunizations, Merck said. GSK said in its statement that it “stands by the safety and effectiveness of our combination vaccines, which are backed by decades of global use and robust science.” Neither company discussed plans to develop single-antigen products.
The reason the timeline is so long is not bureaucratic obstruction. It is the nature of vaccine licensure. Bringing three new single-disease vaccines to market would require each manufacturer to conduct clinical trials in children and obtain separate Biologics License Application approvals from the FDA. This is a regulatory process that historically takes years. There is no shortcut that preserves the safety standards the administration simultaneously claims to be protecting.
The manufacturing complexity compounds the regulatory timeline. Jesse Goodman, former chief scientist at the FDA, noted that manufacturers would be “making three times as many vials or vaccines and filling three times as many,” adding: “It’s not like they have facilities sitting around idle — so they might need to either change current facilities or even create additional capacity for them.”
Merck stopped producing its individual single-antigen vaccines in 2008. Whatever manufacturing infrastructure, validated processes, and quality systems existed for those products has not been maintained. To revive them would be closer to starting from scratch under current Good Manufacturing Practice standards, not so much picking up from where they left.
The market obstacle, not just time
Even if the regulatory and manufacturing challenges were not a time-related obstacle, there is a more fundamental commercial problem: drugmakers are drawing poor reception to the order, with manufacturers and trade groups saying there is no scientific reasoning to follow the directive.
Merck currently sells one combination product that covers three diseases. The executive order is asking it to develop three separate products, each requiring its own clinical program, manufacturing infrastructure, supply chain, and distribution network — at considerably greater total cost — to replace a product that works, is already approved, and is already on formulary. When one vaccine becomes three products, it does not simply create three injections. It creates three supply chains.
There is no obvious upside for the incumbent in that calculation. Three separate visits at three separate prices is more logistically painful for providers and parents, not a growth opportunity for a company already selling the combination product successfully.
Does this create a market opening for anyone else?
The asymmetry between the federal mandate and the incumbent’s commercial incentives is exactly the kind of gap that sometimes attracts smaller developers or biotechs. A regulatory push creating demand for a product the market leader has no reason to build is a classic entry point for a challenger.
No smaller manufacturer or biotech has publicly signalled intent to file for single-antigen MMR components since the executive order. The barriers — clinical trials in children, manufacturing infrastructure, cold chain logistics, and the political uncertainty surrounding whether this policy survives legal challenge or the next administration — are significant disincentives even for companies looking for a federal tailwind.
The reimbursement question nobody has asked
There is a second-order business question sitting underneath all of this that has not appeared in any of the coverage to date. If three separate visits become the recommended standard — whenever that might be — insurers and health systems will need to decide whether they reimburse three pediatric visits the way they currently reimburse one. The combined MMR shot is administered at the 12-month and 4-to-6-year well-child visits, both of which are already covered under preventive care mandates. Three separate visits for each of three separate diseases is a different reimbursement proposition entirely — and nobody in the administration’s order, or in public reporting, has addressed it.
What this means now
No manufacturer sells standalone measles, mumps, or rubella vaccines in the United States, so the MMR provision cannot be acted on today. The executive order is, for now, a signal rather than a mandate, and the manufacturing reality means it will remain a signal for years regardless of what happens politically. cdc
The administration has committed to a policy that the market currently cannot fulfill, directed at an industry that has no commercial reason to fulfill it, on a timeline that the only company with the relevant technology says is measured in decades rather than years.
That gap between the order and what the supply chain can deliver is another story. And it will still be there long after the political noise around the signing has moved on.